SCHEMBL2083997

SCHEMBL2083997

NC1([C@@H]2CCN(c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)C2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.68
KCNH2 Q12809 10/20 0.59
SCN5A Q14524 1/20 0.42
ALDH1A1 P00352 4/20 0.41
POLB P06746 2/20 0.41
OPRM1 P35372 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
OPRD1 P41143 1/20 0.41
KDM4E B2RXH2 4/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 2/20 0.40
PRKD3 O94806 1/20 0.40
ALOX15 P16050 1/20 0.40
CLK2 P49760 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.37
TOP2A P11388 1/20 0.37
TOP2B Q02880 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083993 1.00 CYP3A4 (0.68) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL2083095 0.91 CYP3A4 (0.82) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL2083093 0.91 CYP3A4 (0.82) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL2083994 0.88 CYP3A4 (0.77) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL2083996 0.88 CYP3A4 (0.77) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL2082888 0.85 CYP3A4 (0.65) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL2082885 0.85 CYP3A4 (0.65) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL27593515 0.82 KCNH2 (0.53) CYP3A4KCNH2ALDH1A1POLBOPRM1
SCHEMBL82878 0.81 CYP3A4 (1.00) CYP3A4KCNH2SCN5AALDH1A1POLB
SCHEMBL82879 0.81 CYP3A4 (1.00) CYP3A4KCNH2SCN5AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902226-B2 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
EP-1336611-B1 DEHALOGENO COMPOUNDS DAIICHI SEIYAKU CO (JP) 2007-09-05 EP disclosed
US-20070123560-A1 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. 2007-05-31 US disclosed
US-20040063754-A1 Dehalogeno compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1336611-A1 DEHALOGENO COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063754-A1 Dehalogeno compounds DEK, PGLS, RPS27L CYP3A4 198/4885KCNH2 1597/4885SCN5A 1495/4885
US-20070123560-A1 Dehalogeno-compounds DEK, RPS27L, POLL CYP3A4 277/4885KCNH2 1059/4885SCN5A 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.